Also in 2022, it sold its GeneDx molecular diagnostics business to Sema4 for $ ... testing in oncology was an area of focus and that it continued to expand its test menu in this area, particularly in ...

Virtual Meeting to be held on April 3 hosted by Craig-Hallum. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

GAITHERSBURG, Md., March 04, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today an indication expansion for its ...

We recently published a list of 12 High Growth Low Debt Stocks to Invest in Now. In this article, we are going to take a look ...

GAITHERSBURG, Md., March 20, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of March 15 ...

BTIG analyst Mark Massaro maintained a Buy rating on GeneDx Holdings (WGS – Research Report) yesterday and set a price target of $115.00. The ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever GeneDx Holdings Corp., through its subsidiaries, provides genomics-related ...

--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering ... we're also enriching our database even more rapidly. With each test we gain a deeper understanding of disease-gene relationships ...

GeneDx Holdings Corp. has a one year low of $8.10 and a one year high of $115.60. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx Recognizes Cerebral Palsy Awareness Month with Commitment to Improve Access to Testing GAITHERSBURG, Md.--(BUSINESS WIRE)-- GeneDx (Nasdaq: WGS), a leader in delivering improved health ...

GeneDx recognized for its innovative approach to accelerating genetic diagnosis and transforming the future of healthcare by ending the diagnostic odyssey GeneDx (Nasdaq: WGS), a leader in ...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions will be presented ...